Skip to main content
SpringerLink
Log in

Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The murine monoclonal antibody (MAb) designated DF3, reacts with a 300-kd human mammary epithelial antigen which is expressed on apical borders of secretory mammary epithelial cells and in the cytosol of less differentiated malignant cells. Human mammary tumors have been evaluated for the level of DF3 antigen as a correlate to clinicopathologic parameters related to degree of tumor differentiation: nuclear grade (NG), histologic grade (HG), and estrogen receptor status (ER). More DF3 antigen was present in breast carcinomas with NG 1 and 2 as compared to tumors with NG 3 (p = .002). Similarly DF3 antigen presence was greater in HG 1 and 2 tumors than in HG 3 (p<.001). The results also demonstrate that quantitative differences in the presence of the DF3 differentiation antigen correlate with estrogen receptor status. Twenty-two of 23 ER positive tumors were also DF3 positive. Only 6 of 23 ER negative tumors were reactive to MAb DF3 (p<.001). There was, however, no correlation between DF3 reactivity and absolute levels of estrogen or progesterone receptor.

These findings confirm our hypothesis that MAb DF3 reacts to a differentiation antigen present in some human breast carcinomas. The DF3 antigen phenotype can serve as an independent phenotypic marker with correlations to standard indicators of degree of differentiation and estrogen receptor status of infiltrating ductal carcinomas of the breast, and should thus be evaluated as a prognostic indicator in breast cancer patients. The data also suggests that DF3 histochemistry may be a useful alternative in assessing estrogen receptor status of small breast cancers where there is an insufficient amount of tumor present for biochemical assay of hormone receptor levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223–232, 1984

    PubMed  Google Scholar 

  2. Fisher B, Slack N, Datrych D, Wolmark N: Ten year fol-low-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534, 1975

    PubMed  Google Scholar 

  3. Freedman LS, Edwards DN, McConnell EM, Downham DY: Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 40: 44–55, 1979

    PubMed  Google Scholar 

  4. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers S, et al.: The pathology of invasive breast cancer. Cancer 36: 1–85, 1975

    PubMed  Google Scholar 

  5. Bauer TW, O'Ceallaigh D, Eggleston JC, Moore GW, Baker RR: Prognostic factors in patients with stage I, estrogen receptor-negative carcinoma of the breast: a clinicopathologic study. Cancer 52: 1423–1431, 1983

    PubMed  Google Scholar 

  6. Clark JH, Watson CS, Markaverich BM, Syne JS, Panko WB: Heterogeneity of estrogen binding sites in mammary tumors. Breast Cancer Res Treat 3: 61–75, 1983

    PubMed  Google Scholar 

  7. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B, et al.: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45: 349–353, 1980

    PubMed  Google Scholar 

  8. Fisher ER, Osborne CK, McGuire WL, Redmond C, Knight WA, Fisher B, Bannayan G, Walder A, Gregory EJ, Jacobsen A, Queen DM, Bennett DE, Ford HC: Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1: 37–41, 1981

    PubMed  Google Scholar 

  9. Davis BW, Zava DT, Locher GW, Goldhirsch A, Hartmann WH: Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 20: 375–382, 1984

    PubMed  Google Scholar 

  10. McCarty KW, Barton TK, Fetter BF, Woodard BH, Mossler JA, Reeves W, Daly J, Wilkinson WE, McCarty KS: Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer 46: 2851–2858, 1980

    PubMed  Google Scholar 

  11. Thoresen S, Tangen M, Stoa KF, Hartveit F: Oestrogen receptor values and histological grade in human breast cancer. Histopathology 5: 257–262, 1981

    PubMed  Google Scholar 

  12. Hsu S-M, Raine L, Fanger H: Use of avidin-biotin-peroxi-dase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PA) procedures. J Histochem Cytochem 29: 577–580, 1981

    PubMed  Google Scholar 

  13. Arklie J, Taylor-Papadimitriou J, Bodmer W, Egan M, Millis R: Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer 28: 23–29, 1982

    Google Scholar 

  14. Sloane JP, Omerod MG: Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer 47: 1786–1795, 1981

    PubMed  Google Scholar 

  15. Croghan G, Papsidero L, Valenzuela L, Nemoto T, Penetrante R, Chu M: Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22. Cancer Res 43: 4980–4988, 1983

    PubMed  Google Scholar 

  16. Abe M, Kufe D: Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res (in press), 1984

  17. Leder A, Leder P: Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemia cells. Cell 5: 319–322, 1975

    PubMed  Google Scholar 

  18. Ciocca DR, Adams DJ, Edwards DP, Bjercke R Jr, McGuire WL: Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant tissues and cells. Cancer Res 43: 1204–1210, 1983

    PubMed  Google Scholar 

  19. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer lines. Cell 20: 353–362, 1980

    PubMed  Google Scholar 

  20. Rasmussen BB, Hilkens J, Hilgers J, Nielsen HH, Thorpe SM, Rose C: Monoclonal antibodies applied to primary human breast carcinoma: relationship to menopausal status, lymph node status, and steroid hormone receptor content. Breast Cancer Res Treat 2: 401–405, 1982

    Google Scholar 

  21. Wilkinson MJS, Howell A, Harris M, Papadimitriou JT, Swindell R, Sellwood RA: The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer 33: 299–304, 1984

    PubMed  Google Scholar 

  22. Schnitt SJ, Connolly JL, Harris JR, Hellman S, Cohen RB: Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer 53: 1049–1057, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Connecticut Health Center, Farmington, CN, USA

    Joel Lundy (Director of Surgical Oncology), Faripour Forouhar & Marcia Testa

  2. New Britain General Hospital, New Britain, CN, USA

    Ronald Maenza

  3. Laboratory of Tumor Immunology and Biology, National Cancer Institute, USA

    Joel Lundy (Director of Surgical Oncology), Ann Thor & Jeffrey Schlom

  4. Sidney Farber Cancer Center, Boston, MA, USA

    Donald Kufe

Authors
  1. Joel Lundy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann Thor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald Maenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey Schlom
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Faripour Forouhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcia Testa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Donald Kufe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundy, J., Thor, A., Maenza, R. et al. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res Tr 5, 269–276 (1985). https://doi.org/10.1007/BF01806021

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806021

Keywords

Search

Navigation